Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marta Boffito

Showing results (11-20 of 300) with videos related to

Pageof 30
Sort By:
The AIDS Reader|June 17, 2004
Can we boost enough without ritonavir?Marta Boffito, Graeme J Moyle
The AIDS Reader|April 8, 2004
Pharmacokinetic considerations for combining 2 protease inhibitorsMarta Boffito, Graeme J Moyle
Current Opinion in HIV and AIDS|June 8, 2015
Long-acting antiviral agents for HIV treatmentDavid A Margolis, Marta Boffito
Pharmacogenomics|June 7, 2006
The clinical implications of antiretroviral pharmacogenomicsJulie Fox, Marta Boffito, Alan Winston
Current Opinion in HIV and AIDS|April 19, 2022
Editorial: Is it time to implement injectable antiretroviral treatments globally?Marta Boffito, Kim Scarsi, Chloe Orkin
Current Opinion in Infectious Diseases|November 1, 2005
Host determinants of antiretroviral drug activityMarta Boffito, Alan Winston, Andrew Owen
Current Opinion in Infectious Diseases|November 1, 2016
How recent findings on the pharmacokinetics and pharmacodynamics of integrase inhibitors can inform clinical useEmilie Elliot, Mimie Chirwa, Marta Boffito
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 14, 2014
Pharmacology lessons from chemoprophylaxis studiesMarta Boffito, Akil Jackson, David Asboe
AIDS Reviews|February 11, 2005
Pharmacokinetics and pharmacodynamics of drug interactions involving HIV-1 protease inhibitorsAkil Jackson, Stephen Taylor, Marta Boffito
HIV Medicine|December 25, 2025
Review on: Polypharmacy in HIV: Rethinking what counts and why it mattersMaria Mazzitelli, Marta Boffito, Carlo Torti
Pageof 30

Showing results (11-20 of 300) with videos related to

Sort By:
Pageof 30
The AIDS Reader|June 17, 2004
Can we boost enough without ritonavir?Marta Boffito, Graeme J Moyle
The AIDS Reader|April 8, 2004
Pharmacokinetic considerations for combining 2 protease inhibitorsMarta Boffito, Graeme J Moyle
Current Opinion in HIV and AIDS|June 8, 2015
Long-acting antiviral agents for HIV treatmentDavid A Margolis, Marta Boffito
Pharmacogenomics|June 7, 2006
The clinical implications of antiretroviral pharmacogenomicsJulie Fox, Marta Boffito, Alan Winston
Current Opinion in HIV and AIDS|April 19, 2022
Editorial: Is it time to implement injectable antiretroviral treatments globally?Marta Boffito, Kim Scarsi, Chloe Orkin
Current Opinion in Infectious Diseases|November 1, 2005
Host determinants of antiretroviral drug activityMarta Boffito, Alan Winston, Andrew Owen
Current Opinion in Infectious Diseases|November 1, 2016
How recent findings on the pharmacokinetics and pharmacodynamics of integrase inhibitors can inform clinical useEmilie Elliot, Mimie Chirwa, Marta Boffito
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 14, 2014
Pharmacology lessons from chemoprophylaxis studiesMarta Boffito, Akil Jackson, David Asboe
AIDS Reviews|February 11, 2005
Pharmacokinetics and pharmacodynamics of drug interactions involving HIV-1 protease inhibitorsAkil Jackson, Stephen Taylor, Marta Boffito
HIV Medicine|December 25, 2025
Review on: Polypharmacy in HIV: Rethinking what counts and why it mattersMaria Mazzitelli, Marta Boffito, Carlo Torti
Pageof 30